会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • A PROGNOSTIC AND THERAPEUTIC SIGNATURE FOR MALIGNANT MELANOMA
    • 恶性肿瘤的预防和治疗标志
    • WO2012131052A1
    • 2012-10-04
    • PCT/EP2012/055827
    • 2012-03-30
    • UNIVERSITÄT REGENSBURGETH ZURICHUNIVERSITÄT ZÜRICHMEYER, StefanieBOSSERHOFF, AnjaWILD, PeterFUCHS, Thomas
    • MEYER, StefanieBOSSERHOFF, AnjaWILD, PeterFUCHS, Thomas
    • G01N33/574
    • G01N33/5743G01N2800/52G01N2800/56
    • The present invention relates to a method of predicting the course of disease in a patient having a malignant melanoma, the method comprising determining in melanoma cells comprised in a sample obtained from said malignant melanoma the presence or amount of at least five biomarkers selected from the group comprising or consisting of MTAP, PTEN, Bax, Bcl-X, β-Catenin, CD20, Cox-2, CD49d and MLH1, wherein the absence or decreased amount of MTAP and β-Catenin and/or the presence or increased amount of PTEN, Bax, Bcl-X, CD20, Cox-2, CD49d and MLH1, is associated with a disadvantageous course of disease. The present invention further relates to a method of preparing a tailored pharmaceutical composition for a patient having a malignant melanoma, a kit for predicting the course of disease in a patient having a malignant melanoma, a kit for preparing a tailored pharmaceutical composition for a patient having a malignant melanoma as well as a pharmaceutical composition for use in treating or preventing malignant melanoma.
    • 本发明涉及一种预测具有恶性黑素瘤的患者疾病进程的方法,所述方法包括在从所述恶性黑素瘤获得的样品中包含的黑素瘤细胞中测定选自组中的至少5种生物标志物的存在或量 由MTAP,PTEN,Bax,Bcl-X,β-连环蛋白,CD20,Cox-2,CD49d和MLH1组成或组成,其中不存在或减少量的MTAP和β-连环蛋白和/或存在或增加量的PTEN ,Bax,Bcl-X,CD20,Cox-2,CD49d和MLH1与疾病的不利过程相关。 本发明还涉及制备用于具有恶性黑素瘤的患者的定制药物组合物的方法,用于预测具有恶性黑素瘤的患者的疾病进程的试剂盒,用于制备患者的定制药物组合物的试剂盒, 恶性黑素瘤以及用于治疗或预防恶性黑素瘤的药物组合物。